Letermovir

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Letermovir
Letermovir skeletal.svg
Clinical data
Trade names Prevymis
Synonyms AIC246; MK-8228
Routes of
administration
Oral
ATC code
  • None
Legal status
Legal status
Identifiers
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C29H28F4N4O4
Molar mass 572.56 g·mol−1
3D model (JSmol)

Letermovir (INN; trade name Prevymis) is an antiviral drug for the treatment of cytomegalovirus (CMV) infections. It has been tested in CMV infected patients with allogeneic stem cell transplants and may also be useful for other patients with a compromised immune system such as those with organ transplants or HIV infections.[1] The drug was developed by Merck & Co., Inc as investigative compound MK-8228.[2]

The drug was granted fast track status by the US Food and Drug Administration (FDA) and orphan drug status by the European Medicines Agency.[1] In the United States, it is approved for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant.[3]

References[edit]

  1. ^ a b "Neues Virostatikum Letermovir" (in German). Deutsche Apothekerzeitung. 2011-08-29. 
  2. ^ Masangkay, Estel Grace (July 29, 2014). "Merck Kicks Off Phase 3 Study Of CMV Drug Letermovir". Retrieved 8 Oct 2014. 
  3. ^ "FDA Approves Letermovir for CMV Prophylaxis Post-Transplantation". onclive.com. November 9, 2017.